Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Fig. 4

a Cell cycle evaluation: percentage of cells at different cell cycle phases after treatment with 100 nM KPT-330 at different times (24, 48 and 72 hrs). b-g Molecular arrangements associated to CRM1 inhibition: b, c Survivin nuclear accumulation. Western blot b in PC3 cells treated with 100 nM KPT-330 for 4, 8, 12 and 24 hrs. c ELISA determinations in PC3 cells treated with 100 nM KPT-330 for 4, 8,m 12, 24, 48 and 72; d western blots for protein associated with apoptosis (Bax and Bcl-2 family members) and caspases. e Activity of caspase 8; f activity of caspase 9. g Cytofluorimetric analysis of apoptosis

Back to article page
\